Mycobacterium avium ssp. paratuberculosis and Crohn’s Disease—Diagnostic Microbiological Investigations Can Inform New Therapeutic Approaches
Antibiotics · 05.02.2024 · 13 (2) · 158
DOI: 10.3390/antibiotics13020158 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 05.02.2024. Verfasst von John M Aitken und 2 weiteren Autor:innen. Beteiligte Einrichtung: Otakaro Pathways Ltd., Innovation Park, Christchurch 7675, New Zealand. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mycobacterium avium ssp. paratuberculosis (MAP) is the cause of Johne’s disease (JD), which is a chronic infectious gastrointestinal disease of ruminants and is often fatal. In humans, MAP has been associated with Crohn’s disease (CD) for over a century, without conclusive evidence of pathogenicity. Numerous researchers have contributed to the subject, but there is still a need for evidence of the causation of CD by MAP. An infectious aetiology in CD that is attributable to MAP can only be proven by bacteriological investigations. There is an urgency in resolving this question due to the rising global incidence rates of CD. Recent papers have indicated the “therapeutic ceiling” may be close in the development of new biologics. Clinical trial outcomes have demonstrated mild or inconsistent improvements in therapeutic interventions over the last decades when compared with placebo. The necessity to revisit therapeutic options for CD is becoming more urgent and a renewed focus on causation is essential for progress in identifying new treatment options. This manuscript discusses newer interventions, such as vaccination, FMT, dietary remediation and gut microbiome regulation, that will become more relevant as existing therapeutic options expire. Revisiting the MAP theory as a potential infectious cause of CD, rather than the prevailing concept of an “aberrant immune response” will require expanding the current therapeutic programme to include potential new alternatives, and combinations of existing treatments. To advance research on MAP in humans, it is essential for microbiologists and medical scientists to microscopically detect CWDM and to biologically amplify the growth by directed culture.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Otakaro Pathways Ltd., Innovation Park, Christchurch 7675, New Zealand.
- Division of Diabetes & Nutritional Sciences, Franklin-Wilkins Building, King's College London, London SE1 9NH, UK.
ORCID-Profile: Gaurav Agrawal
Zitieren
APA
Aitken, J. M., Aitken, J. E., & Agrawal, G. (2024). Mycobacterium avium ssp. paratuberculosis and Crohn’s Disease—Diagnostic Microbiological Investigations Can Inform New Therapeutic Approaches. Antibiotics, 13(2), 158. https://doi.org/10.3390/antibiotics13020158
Vancouver
Aitken JM, Aitken JE, Agrawal G. Mycobacterium avium ssp. paratuberculosis and Crohn’s Disease—Diagnostic Microbiological Investigations Can Inform New Therapeutic Approaches. Antibiotics. 2024;13(2):158. doi:10.3390/antibiotics13020158
BibTeX
@article{Aitken2024,
author = {Aitken, John M and Aitken, Jack E and Agrawal, Gaurav},
title = {Mycobacterium avium ssp. paratuberculosis and Crohn’s Disease—Diagnostic Microbiological Investigations Can Inform New Therapeutic Approaches},
journal = {Antibiotics},
year = {2024},
volume = {13},
number = {2},
pages = {158},
doi = {10.3390/antibiotics13020158}
}
EUVIMED